LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

11.7 1.3

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.36

Max

12.09

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+64.64% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.52%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-127M

241M

Iepriekšējā atvēršanas cena

10.4

Iepriekšējā slēgšanas cena

11.7

Ziņu noskaņojums

By Acuity

27%

73%

86 / 349 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. marts 23:43 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

2026. g. 26. marts 23:36 UTC

Tirgus saruna
Galvenie ziņu notikumi

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

2026. g. 26. marts 23:35 UTC

Iegādes, apvienošanās, pārņemšana

Pernod Ricard: Confirms Discussions With Brown-Forman

2026. g. 26. marts 23:29 UTC

Peļņas

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

2026. g. 26. marts 23:28 UTC

Peļņas

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

2026. g. 26. marts 23:28 UTC

Peļņas

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

2026. g. 26. marts 23:28 UTC

Peļņas

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

2026. g. 26. marts 23:27 UTC

Peļņas

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

2026. g. 26. marts 23:27 UTC

Peļņas

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

2026. g. 26. marts 23:08 UTC

Tirgus saruna

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

2026. g. 26. marts 23:04 UTC

Iegādes, apvienošanās, pārņemšana

Pernod in Deal Talks With Brown-Forman -- WSJ

2026. g. 26. marts 22:41 UTC

Iegādes, apvienošanās, pārņemšana

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

2026. g. 26. marts 22:41 UTC

Iegādes, apvienošanās, pārņemšana

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

2026. g. 26. marts 22:26 UTC

Peļņas

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

2026. g. 26. marts 22:26 UTC

Peļņas

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

2026. g. 26. marts 22:26 UTC

Peļņas

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

2026. g. 26. marts 22:08 UTC

Peļņas

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

2026. g. 26. marts 22:08 UTC

Peļņas

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

2026. g. 26. marts 22:08 UTC

Peļņas

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

2026. g. 26. marts 22:07 UTC

Tirgus saruna
Galvenie ziņu notikumi

Global Energy Roundup: Market Talk

2026. g. 26. marts 22:07 UTC

Tirgus saruna
Galvenie ziņu notikumi

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

2026. g. 26. marts 22:00 UTC

Peļņas

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

2026. g. 26. marts 22:00 UTC

Peļņas

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

2026. g. 26. marts 22:00 UTC

Peļņas

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

2026. g. 26. marts 21:39 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

2026. g. 26. marts 21:38 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

64.64% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  64.64%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

86 / 349 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat